Google
Trusted Resources: News & Events
Latest announcements and gatherings
Pfizer Executive Outlines Vision for Treating Sickle Cell Disease, Other Rare Diseases
Consumers may know Pfizer as the company that manufactures Viagra, but the New York-based pharma giant is investing millions in developing potential treatments and gene therapies for rare disorders ranging from sickle cell disease and hemophilia to ALS and Duchenne muscular dystrophy.
Michael Wajnrajch, MD, is senior medical director for Pfizer’s Rare Disease Group and pediatric endocrinologist on the faculty of New York University. Wajnrajch outlined his company’s vision for gene therapies at the 2nd International Congress on Advanced Treatments in Rare Diseases, held March 4-5 in Vienna, Austria.
“Sometimes we’re doing the right thing for the right reasons, and it’s not about the money,” he told some 100 delegates. “Sickle cell disease predominantly affects patients with very limited ability to pay. We’re not going to make much money on this, but we know it’s an unmet medical need in many parts of the world.”
+myBinderRelated Content
-
The Affordable Care Act Improves Healthcare Access and Utilization Among Young Adults with Sickle Cell DiseaseIntroduction: The Dependent Coverage Pro...
-
Sickle Cell Breakthrough: Shauna’s Storyhttps://www.youtube.com/watch?v=Q-kXWV-s...
-
Interventions for Patients and Caregivers to Improve Knowledge of Sickle Cell Disease and Recognition of Its Related...Background: Sickle cell disease is a gr...
-
Edward Donnell IvyEdward Donnell Ivy is a Director of Outr...
-
First World Cord Blood Day on Nov. 15 to Highlight Cord Blood Uses, Stem Cell ResearchThe inaugural World Cord Blood Day on No...
-
GBT and SCDAA Kick Off “Lift Every Voice to Shine the Light on Sickle Cell”In recognition of World Sickle Cell Day,...
-
Betty Pace, MDDr. Betty Pace is a pediatric hematologi...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.